GO:0010757 negative regulation of plasminogen activation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010757 (negative regulation of plasminogen activation) describes any process that decreases the rate, frequency or extent of plasminogen conversion to plasmin, the central protease of the fibrinolytic system.
• The plasminogen activation system is controlled at multiple levels, including transcriptional regulation of PAI-1, posttranscriptional regulation by non-coding RNAs, and growth factor signaling.
• FGF-2 signaling through phosphoinositide 3-kinase (PI3K) negatively regulates urokinase-type plasminogen activator (uPA) production, providing a direct example of negative regulation.
• HMGA1 regulates the plasminogen activation system in the secretome of breast cancer cells, linking chromatin-associated factors to negative control of plasminogen activation.
• FXR activation in hepatocytes enhances fibrinolysis and reduces deep vein thrombosis risk, demonstrating that nuclear receptor signaling can modulate plasminogen activation.
• Non-coding RNAs, including microRNAs and long non-coding RNAs, posttranscriptionally regulate the plasminogen activation system in cancer, offering therapeutic targets.
Description
Plasminogen activation is the proteolytic conversion of the zymogen plasminogen into the active serine protease plasmin, which degrades fibrin clots and remodels the extracellular matrix. Because unrestrained plasmin activity can cause excessive bleeding, tissue damage, or promote cancer invasion, negative regulation of plasminogen activation (GO:0010757) is essential for maintaining hemostatic balance and tissue homeostasis. This GO term encompasses any process that decreases the rate, frequency, or extent of plasminogen activation, including inhibition of plasminogen activators, enhancement of plasminogen activator inhibitors, and transcriptional or posttranscriptional suppression of pathway components. Researchers study GO:0010757 to understand how cells and organisms prevent inappropriate plasmin generation. The plasminogen activation system is dysregulated in thrombosis, cancer, and inflammatory diseases, making its negative regulation a topic of intense investigation. For example, FGF-2-mediated activation of phosphoinositide 3-kinase (PI3K) suppresses urokinase-type plasminogen activator (uPA) production, illustrating a signaling pathway that negatively regulates plasminogen activation. Similarly, HMGA1 modulates the plasminogen activation system in the secretome of breast cancer cells, and non-coding RNAs posttranscriptionally control pathway components in cancer. Understanding the molecular players and regulatory logic of GO:0010757 is critical for developing therapeutics that either promote or inhibit plasminogen activation in diseases such as deep vein thrombosis, cancer metastasis, and metabolic disorders. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of the term, its mechanisms, key genes, disease relevance, and experimental approaches.
negative regulation of plasminogen activation At A Glance
| GO ID | GO:0010757 |
|---|---|
| GO term | negative regulation of plasminogen activation |
| Ontology | biological_process |
| Synonym | inhibition of plasminogen activation |
| Definition | Any process that decreases the rate, frequency or extent of plasminogen activation. Plasminogen activation is the process in which plasminogen is processed to plasmin. |
| Major function | Limits plasmin generation, thereby controlling fibrinolysis, extracellular matrix remodeling, and cell migration. |
| Key regulators | PAI-1, uPA, tPA, FGF-2/PI3K signaling, HMGA1, non-coding RNAs, FXR. |
| Disease relevance | Thrombosis, cancer metastasis, inflammation, metabolic disorders. |
What Is GO:0010757?
GO:0010757 (negative regulation of plasminogen activation) is a biological process term defined as any process that decreases the rate, frequency or extent of plasminogen activation. Plasminogen activation itself is the process in which plasminogen is processed to plasmin. Thus, negative regulation of plasminogen activation includes mechanisms that reduce the production or activity of plasminogen activators (such as uPA and tPA), increase the activity of plasminogen activator inhibitors (such as PAI-1), or otherwise limit the conversion of plasminogen to plasmin.
Why Is negative regulation of plasminogen activation Important in Cell Biology?
Negative regulation of plasminogen activation is essential for preventing excessive proteolysis that could lead to bleeding, tissue damage, or pathological cell invasion. The plasminogen activation system is a major drug target in cardiovascular disease and cancer, and understanding its negative regulation provides opportunities to modulate fibrinolysis and metastasis. For instance, activation of FXR in hepatocytes enhances fibrinolysis and reduces deep vein thrombosis risk, highlighting the therapeutic potential of targeting negative regulators. In cancer, non-coding RNAs that suppress plasminogen activation can limit metastasis, making them attractive for RNA-based therapies.
• Maintains hemostatic balance by preventing excessive plasmin generation and fibrinolysis.
• Controls extracellular matrix remodeling, which affects cell migration, invasion, and tissue repair.
• Dysregulation is linked to thrombotic disorders such as deep vein thrombosis.
• Plays a role in cancer progression and metastasis by modulating uPA and PAI-1 levels.
• Involved in metabolic and inflammatory conditions, including negative energy balance in dairy cows.
• Provides targets for therapeutic intervention in cardiovascular disease and cancer.
• Regulated by growth factor signaling pathways such as FGF-2/PI3K.
• Modulated by chromatin-associated factors like HMGA1.
• Posttranscriptionally controlled by microRNAs and long non-coding RNAs.
• Impacts catecholaminergic function and neuroendocrine regulation.
What Happens During negative regulation of plasminogen activation?
Inhibition of plasminogen activators
In simple terms: The process blocks the enzymes that turn plasminogen into plasmin.
Plasminogen activation is primarily mediated by urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA). Negative regulation can occur through direct inhibition of these enzymes or by reducing their production. For example, FGF-2 signaling through PI3K negatively regulates uPA production, thereby decreasing plasminogen activation. This mechanism helps control the extent of proteolysis in tissues.
Upregulation of plasminogen activator inhibitors
In simple terms: The process increases molecules that block plasminogen activators.
Plasminogen activator inhibitor type 1 (PAI-1) is a major physiological inhibitor of uPA and tPA. Transcriptional regulation of PAI-1, with an emphasis on negative regulation, is critical for controlling plasminogen activation. Increased PAI-1 expression reduces plasmin generation and is associated with thrombotic risk and cancer progression.
Transcriptional control of pathway components
In simple terms: The process changes how genes for the plasminogen activation system are turned on or off.
Transcriptional regulation of PAI-1 and other components is a key node in negative regulation. Nagamine (2008) reviewed the transcriptional regulation of PAI-1 with an emphasis on negative regulation, highlighting how transcription factors and signaling pathways modulate PAI-1 gene expression. Similarly, HMGA1 regulates the plasminogen activation system in the secretome of breast cancer cells, affecting the balance of activators and inhibitors.
Posttranscriptional regulation by non-coding RNAs
In simple terms: Small RNA molecules can reduce the production of proteins that activate plasminogen.
Non-coding RNAs, including microRNAs and long non-coding RNAs, posttranscriptionally regulate the plasminogen activation system in cancer. For instance, multi-targeted non-coding RNA regulation nanoplatforms have been developed to suppress metastasis and recurrence of triple-negative breast cancer by modulating the plasminogen activation system. These mechanisms add another layer of negative control.
Signaling pathways that suppress plasminogen activation
In simple terms: External signals can tell cells to reduce plasminogen activation.
Growth factor signaling can negatively regulate plasminogen activation. FGF-2-mediated activation of phosphoinositide 3-kinase (PI3K) decreases uPA production, thereby reducing plasminogen activation. Additionally, FXR activation in hepatocytes enhances fibrinolysis and reduces deep vein thrombosis risk, indicating that nuclear receptor signaling can modulate the pathway. These pathways integrate physiological cues to fine-tune plasmin generation.
Key Genes Involved in GO:0010757 negative regulation of plasminogen activation
The following genes and proteins are central to the negative regulation of plasminogen activation, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SERPINE1 (PAI-1) | Primary inhibitor of uPA and tPA; directly blocks plasminogen activation | Transcriptional regulation studied in thrombosis and cancer |
| PLAU (uPA) | Plasminogen activator; its production is negatively regulated by FGF-2/PI3K | Target of negative regulation in cancer and inflammation |
| PLAT (tPA) | Plasminogen activator; inhibited by PAI-1 | Key enzyme in fibrinolysis; regulated in thrombosis |
| PLG (Plasminogen) | Zymogen precursor of plasmin; its activation is the target of negative regulation | Central to fibrinolysis and extracellular matrix remodeling |
| FGF2 | Growth factor that activates PI3K to suppress uPA production | Signaling pathway that negatively regulates plasminogen activation |
| PIK3CA/PIK3CB | PI3K subunits mediating FGF-2-induced negative regulation of uPA | Potential targets to modulate plasminogen activation |
| HMGA1 | Chromatin-associated factor regulating plasminogen activation system in secretome | Breast cancer cell secretome regulation |
| NR1H4 (FXR) | Nuclear receptor; activation enhances fibrinolysis and reduces DVT risk | Therapeutic target for thrombosis |
| MIRNAs (e.g., miR-21, miR-31) | Posttranscriptional regulators of plasminogen activation components | Non-coding RNA-based therapy in cancer |
| LncRNAs | Long non-coding RNAs modulating plasminogen activation system | Cancer metastasis and recurrence |
| IL6 | Interleukin-6; linked to plasminogen regulation in negative energy balance | Metabolic and inflammatory regulation |
| PLAUR (uPAR) | Receptor for uPA; modulates plasminogen activation at cell surface | Cancer invasion and metastasis |
| SERPINB2 (PAI-2) | Inhibitor of uPA; contributes to negative regulation | Placental and inflammatory contexts |
| TGFB1 | Cytokine that can induce PAI-1 expression | Fibrosis and cancer |
| TNF | Inflammatory cytokine modulating PAI-1 and uPA | Inflammation and thrombosis |
| HIF1A | Hypoxia-inducible factor; regulates PAI-1 and uPA | Cancer and ischemia |
| MYC | Oncogene that can influence plasminogen activation system | Cancer progression |
| SP1 | Transcription factor regulating PAI-1 promoter | Transcriptional control of negative regulation |
How Is negative regulation of plasminogen activation Regulated?
Negative regulation of plasminogen activation is controlled at multiple levels. Transcriptionally, PAI-1 gene expression is modulated by various transcription factors and signaling pathways, with negative regulation being a key focus. Growth factor signaling, such as FGF-2 via PI3K, suppresses uPA production. Nuclear receptor FXR activation in hepatocytes enhances fibrinolysis and reduces deep vein thrombosis risk, indicating a role in negative regulation. Posttranscriptionally, non-coding RNAs including microRNAs and long non-coding RNAs regulate the plasminogen activation system in cancer. Additionally, chromatin-associated HMGA1 regulates the system in breast cancer secretome. Metabolic and inflammatory states, such as negative energy balance in dairy cows, also influence plasminogen regulation.
negative regulation of plasminogen activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SERPINE1 (PAI-1) | Thrombosis, cardiovascular disease | KO and overexpression in endothelial cells; thrombosis mouse models |
| PLAU (uPA) | Cancer metastasis, inflammation | Knockout in cancer cell lines; xenograft models |
| NR1H4 (FXR) | Deep vein thrombosis | Hepatocyte-specific KO; FXR agonist treatment in mice |
| HMGA1 | Breast cancer | Knockdown in breast cancer cells; secretome analysis |
| MIRNAs | Triple-negative breast cancer | miRNA mimics/inhibitors; nanoplatform delivery in mice |
Thrombosis and cardiovascular disease
Negative regulation of plasminogen activation is critical for preventing excessive fibrinolysis, but when overactive, it can promote thrombosis. Activation of FXR in hepatocytes enhances fibrinolysis and reduces deep vein thrombosis risk, demonstrating that modulating negative regulators can be therapeutic. PAI-1, a key negative regulator, is a risk factor for thrombotic disorders.
Cancer progression and metastasis
The plasminogen activation system is dysregulated in cancer, where it promotes invasion and metastasis. Negative regulation by non-coding RNAs can suppress these processes; for example, multi-targeted non-coding RNA nanoplatforms against triple-negative breast cancer modulate the system to inhibit metastasis and recurrence. HMGA1 regulation of the plasminogen activation system in breast cancer secretome further highlights its role in cancer biology. Posttranscriptional regulation by non-coding RNAs is a growing area of cancer research.
Inflammatory and metabolic disorders
Inflammatory cytokines such as IL-6 and TNF can influence plasminogen activation. In Simmental cows with negative energy balance, regulation of interleukin-6 and plasminogen was observed, linking metabolic stress to the plasminogen system. The plasminogen activation system also regulates catecholaminergic function, suggesting broader neuroendocrine roles.
From negative regulation of plasminogen activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PAI-1 increase plasminogen activation? | SERPINE1 knockout cell line (e.g., HUVEC) and plasminogen activation assays |
| Does FGF-2/PI3K signaling negatively regulate uPA? | PIK3CA point mutation or knockout in fibroblasts; uPA ELISA |
| Does FXR activation reduce thrombosis via fibrinolysis? | Hepatocyte-specific FXR knockout mice; DVT models |
| Does HMGA1 regulate the plasminogen activation secretome? | HMGA1 knockout breast cancer cells; proteomics of conditioned media |
| Can non-coding RNAs suppress metastasis by targeting plasminogen activation? | miRNA overexpression or sponge in TNBC cells; metastasis mouse models |
| Does a specific SNP in SERPINE1 affect PAI-1 levels? | CRISPR knock-in of SNP in hepatocytes; PAI-1 expression assays |
How to Study the negative regulation of plasminogen activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of plasminogen activation genes | Transcriptional regulation studies |
| Small RNA-seq | microRNA and other non-coding RNA expression | Posttranscriptional regulation in cancer |
| Proteomics (secretome) | Protein levels of uPA, PAI-1, etc. in conditioned media | HMGA1 regulation in breast cancer |
| Chromogenic plasminogen activation assay | Plasmin generation rate | Functional assessment of negative regulators |
| ELISA | uPA, tPA, PAI-1 protein concentrations | Quantification in cell lysates and plasma |
| CRISPR knockout screen | Genes whose loss alters plasminogen activation | Discovery of novel negative regulators |
| CRISPR activation (CRISPRa) | Genes whose overexpression suppresses plasminogen activation | Identification of negative regulators |
| Western blot | Protein levels and cleavage of plasminogen | Validation of regulatory mechanisms |
Transcriptional and posttranscriptional analysis
RNA-seq and qRT-PCR can quantify mRNA levels of plasminogen activation components such as PLAU, PLAT, and SERPINE1. Non-coding RNA regulation can be studied using small RNA-seq and crosslinking immunoprecipitation (CLIP). These methods reveal how negative regulation is achieved at the RNA level.
Proteomic and secretome analysis
Mass spectrometry-based proteomics of conditioned media (secretome) can identify changes in plasminogen activation system proteins, as demonstrated for HMGA1 in breast cancer cells. This approach measures the functional output of negative regulation.
Enzymatic activity assays
Plasminogen activation can be measured using chromogenic or fluorogenic substrates that detect plasmin generation. uPA and tPA activities can be quantified in cell lysates or conditioned media, and PAI-1 activity can be assessed using commercial kits.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate plasminogen activation. For example, a screen for regulators of uPA production could use a uPA promoter-driven reporter. These screens are powerful for discovering novel regulators.
How CRISPR Can Be Used to Study GO:0010757 negative regulation of plasminogen activation
Knockout
CRISPR knockout of negative regulators such as SERPINE1 (PAI-1) can be used to assess their role in plasminogen activation. Loss of PAI-1 is expected to increase plasmin generation, confirming its negative regulatory function. Knockout of FGF2 or PIK3CA can test the FGF-2/PI3K pathway's role in suppressing uPA.
Point Mutation
Point mutations can be introduced into regulatory regions or coding sequences to mimic disease-associated variants. For example, a SNP in the SERPINE1 promoter that affects PAI-1 expression can be knocked into hepatocytes to study its impact on plasminogen activation. Point mutations in the uPA active site can also be generated to study substrate specificity.
Knock-in
Knock-in of reporter genes (e.g., luciferase) under the control of the PLAU or SERPINE1 promoter allows real-time monitoring of negative regulation. Tagged knock-in of PAI-1 with a fluorescent protein enables tracking of its secretion and localization.
Overexpression
Overexpression of negative regulators such as PAI-1 or non-coding RNAs can suppress plasminogen activation and reduce metastasis in cancer models. CRISPR activation (CRISPRa) can be used to overexpress endogenous genes, providing a more physiological context.
How EDITGENE Supports negative regulation of plasminogen activation Research
Researchers studying negative regulation of plasminogen activation-related genes often need to determine whether a candidate gene is causally involved in suppressing plasmin generation. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of plasminogen activation research.
Frequently Asked Questions About negative regulation of plasminogen activation
What is negative regulation of plasminogen activation?
Negative regulation of plasminogen activation (GO:0010757) is any process that decreases the rate, frequency or extent of plasminogen conversion to plasmin, the active protease in fibrinolysis.
What genes are involved in negative regulation of plasminogen activation?
Key genes include SERPINE1 (PAI-1), PLAU (uPA), PLAT (tPA), FGF2, PIK3CA, HMGA1, and NR1H4 (FXR), as well as non-coding RNAs.
How is plasminogen activation negatively regulated?
It is regulated by inhibitors such as PAI-1, by signaling pathways like FGF-2/PI3K that suppress uPA production, and by transcriptional and posttranscriptional mechanisms including non-coding RNAs.
What diseases are associated with negative regulation of plasminogen activation?
Thrombosis, deep vein thrombosis, cancer metastasis, and inflammatory or metabolic disorders are associated with dysregulation of this process.
What is the role of PAI-1 in negative regulation of plasminogen activation?
PAI-1 (encoded by SERPINE1) is the primary inhibitor of uPA and tPA, directly blocking plasminogen activation and thus serving as a major negative regulator.
How do non-coding RNAs regulate plasminogen activation?
Non-coding RNAs, including microRNAs and long non-coding RNAs, posttranscriptionally regulate the plasminogen activation system by targeting mRNAs of components such as uPA and PAI-1.
Can CRISPR be used to study negative regulation of plasminogen activation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of genes involved in this process.
What experimental models are used to study negative regulation of plasminogen activation?
Common models include knockout cell lines, hepatocyte-specific knockout mice, and xenograft models, combined with plasminogen activation assays and proteomics.
What is the clinical significance of negative regulation of plasminogen activation?
It is clinically significant because modulating this process can influence thrombosis risk and cancer progression, making it a therapeutic target.
How does FGF-2 signaling negatively regulate plasminogen activation?
FGF-2 activates phosphoinositide 3-kinase (PI3K), which decreases uPA production, thereby reducing plasminogen activation.
Conclusion
GO:0010757 (negative regulation of plasminogen activation) is a critical biological process that controls the conversion of plasminogen to plasmin, thereby influencing fibrinolysis, extracellular matrix remodeling, and cell migration. Its dysregulation is implicated in thrombosis, cancer, and metabolic disorders. Key regulators include PAI-1, uPA, FGF-2/PI3K signaling, HMGA1, FXR, and non-coding RNAs. Understanding these mechanisms offers therapeutic opportunities, and CRISPR-based models are invaluable for dissecting the causal roles of specific genes. EDITGENE provides comprehensive services to support such research.
References
- 1. Alfieri M et al.. 2023. Posttranscriptional Regulation of the Plasminogen Activation System by Non-Coding RNA in Cancer.. Int J Mol Sci 24(2) PMID: 36674481
- 2. Bai H et al.. 2012. The plasminogen activation system and the regulation of catecholaminergic function.. J Biomed Biotechnol 2012:721657 PMID: 23097598
- 3. Li B et al.. 2025. Targeting FXR in hepatocytes: a promising approach to enhance fibrinolysis and reduce deep vein thrombosis risk.. Blood 146(20):2464-2478 PMID: 40864969
- 4. Mochizuki Y et al.. 2002. Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase.. Oncogene 21(46):7027-33 PMID: 12370824
- 5. Wnorowska K et al.. 2025. Molecular Response of Simmental Cows to Negative Energy Balance: Regulation of Interleukin-6 and Plasminogen During Early Lactation.. Int J Mol Sci 26(23) PMID: 41373870
- 6. Song L et al.. 2023. Multi-Targeted and On-Demand Non-Coding RNA Regulation Nanoplatform against Metastasis and Recurrence of Triple-Negative Breast Cancer.. Small 19(23):e2207576 PMID: 36905244
- 7. Nagamine Y. 2008. Transcriptional regulation of the plasminogen activator inhibitor type 1--with an emphasis on negative regulation.. Thromb Haemost 100(6):1007-13 PMID: 19132223
- 8. Resmini G et al.. 2017. HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.. Sci Rep 7(1):11768 PMID: 28924209
